Recovery Investigational

ARA-290

An erythropoietin-derived peptide fragment studied for tissue-protective and neuropathy-related applications without the red-blood-cell effects of full EPO.

NeuropathyTissue ProtectionInvestigational

Also referenced as: Cibinetide

Price compare

46 tracked offers across 46 vendors · 19 dosages

Best trust-adjusted value: Southern Aminos · Moderate trust · $2.21/mg

From

$2.21/mg

Status

Investigational

This compound has a genuine development or study trail, but it is not an approved routine drug.

Category

Recovery

This profile is grouped by its dominant research and market lane, not by vendor shelf placement.

Aliases

Cibinetide

Signal depth

Medium

No FDA label signal · 4 trials · 77 PubMed results

Promising

Research evidence

ARA-290 has name-matched human trials with published or reported controlled evidence, but is not FDA-approved. The research is real and ongoing — treat findings as developing rather than settled.

ARA-290 has 3 name-matched clinical trials (1 international) (highest phase: Phase 2) and 77 PubMed-indexed publications and is not FDA-approved. 1 trial has posted results. Note: 2 retracted publications in the literature.

🌍 1 international trial ⚠ 2 retracted publications

Human data

Phase 2

Trial quality

Randomized

Outcomes

Clinical outcomes

Replication

Multiple trials

Literature

Established

PHASE2 · Randomized Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoidosis PHASE2 · Randomized ARA290 in T2D (Effects of ARA 290, an Erythropoietin Analogue) in Prediabetes and Type 2 Diabetes) ISRCTN · Phase 2 Use of ARA 290 for the treatment of diabetic macular oedema Molecular Medicine · 143 citations ARA 290, a Nonerythropoietic Peptide Engineered from Erythropoietin, Improves Metabolic Control and Neuropathic Symptoms in Patients with Type 2 Diabetes Molecular Medicine · 110 citations Safety and Efficacy of ARA 290 in Sarcoidosis Patients with Symptoms of Small Fiber Neuropathy: A Randomized, Double-Blind Pilot Study Investigative Ophthalmology & Visual Science · 103 citations Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain

Evidence history

Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-07-13 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →

What ARA-290 is

ARA-290 is a small peptide derived from the tissue-protective region of erythropoietin. It is usually discussed as a way to explore anti-inflammatory and repair-oriented signaling without using full erythropoietin as a drug.

Why it matters

It shows up in the peptide market because it sits at the intersection of pain, small-fiber neuropathy, and tissue recovery. That gives it a very different profile from the more common tendon-and-muscle repair peptides.

Regulatory context

ARA-290 is not an FDA-approved therapy in the United States. It is best understood as an investigational compound with a more clinical backstory than many research-market entries.

Practical reading note

When this compound appears in vendor catalogs, the important distinction is that investigational interest does not equal routine clinical availability.